Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 84

1.

The new small molecule tyrosine-kinase inhibitor ARQ531 targets acute myeloid leukemia cells by disrupting multiple tumor-addicted programs.

Soncini D, Orecchioni S, Ruberti S, Minetto P, Martinuzzi C, Agnelli L, Todoerti K, Cagnetta A, Miglino M, Clavio M, Contini P, Varaldo R, Bergamaschi M, Guolo F, Passalacqua M, Nencioni A, Monacelli F, Gobbi M, Neri A, Abbadessa G, Eathiraj S, Schwartz B, Bertolini F, Lemoli RM, Cea M.

Haematologica. 2019 Oct 17. pii: haematol.2019.224956. doi: 10.3324/haematol.2019.224956. [Epub ahead of print]

2.

Long non-coding RNA NEAT1 targeting impairs the DNA repair machinery and triggers anti-tumor activity in multiple myeloma.

Taiana E, Favasuli V, Ronchetti D, Todoerti K, Pelizzoni F, Manzoni M, Barbieri M, Fabris S, Silvestris I, Gallo Cantafio ME, Platonova N, Zuccalà V, Maltese L, Soncini D, Ruberti S, Cea M, Chiaramonte R, Amodio N, Tassone P, Agnelli L, Neri A.

Leukemia. 2019 Aug 19. doi: 10.1038/s41375-019-0542-5. [Epub ahead of print]

PMID:
31427718
3.

The transcriptomic profile of CD138+ cells from patients with early progression from smoldering to active multiple myeloma remains substantially unchanged.

Storti P, Agnelli L, Palma BD, Todoerti K, Marchica V, Accardi F, Sammarelli G, Deluca F, Toscani D, Costa F, Vicario E, Todaro G, Martella E, Neri A, Giuliani N.

Haematologica. 2019 Oct;104(10):e465-e469. doi: 10.3324/haematol.2018.209999. Epub 2019 Mar 7. No abstract available.

4.

Expanding the repertoire of miRNAs and miRNA-offset RNAs expressed in multiple myeloma by small RNA deep sequencing.

Agnelli L, Bisognin A, Todoerti K, Manzoni M, Taiana E, Galletti S, Cutrona G, Gaffo E, Bortoluzzi S, Neri A.

Blood Cancer J. 2019 Feb 19;9(3):21. doi: 10.1038/s41408-019-0184-x.

5.

A GBM-like V-ATPase signature directs cell-cell tumor signaling and reprogramming via large oncosomes.

Bertolini I, Terrasi A, Martelli C, Gaudioso G, Di Cristofori A, Storaci AM, Formica M, Braidotti P, Todoerti K, Ferrero S, Caroli M, Ottobrini L, Vaccari T, Vaira V.

EBioMedicine. 2019 Mar;41:225-235. doi: 10.1016/j.ebiom.2019.01.051. Epub 2019 Feb 6.

6.

IDH2 inhibition enhances proteasome inhibitor responsiveness in hematological malignancies.

Bergaggio E, Riganti C, Garaffo G, Vitale N, Mereu E, Bandini C, Pellegrino E, Pullano V, Omedè P, Todoerti K, Cascione L, Audrito V, Riccio A, Rossi A, Bertoni F, Deaglio S, Neri A, Palumbo A, Piva R.

Blood. 2019 Jan 10;133(2):156-167. doi: 10.1182/blood-2018-05-850826. Epub 2018 Nov 19.

PMID:
30455381
7.

Global methylation patterns in primary plasma cell leukemia.

Todoerti K, Calice G, Trino S, Simeon V, Lionetti M, Manzoni M, Fabris S, Barbieri M, Pompa A, Baldini L, Bollati V, Zoppoli P, Neri A, Musto P.

Leuk Res. 2018 Oct;73:95-102. doi: 10.1016/j.leukres.2018.09.007. Epub 2018 Sep 18.

PMID:
30257227
8.

Long non-coding RNA NEAT1 shows high expression unrelated to molecular features and clinical outcome in multiple myeloma.

Taiana E, Ronchetti D, Favasuli V, Todoerti K, Manzoni M, Amodio N, Tassone P, Agnelli L, Neri A.

Haematologica. 2019 Feb;104(2):e72-e76. doi: 10.3324/haematol.2018.201301. Epub 2018 Sep 13. No abstract available.

9.

miR-22 suppresses DNA ligase III addiction in multiple myeloma.

Caracciolo D, Di Martino MT, Amodio N, Morelli E, Montesano M, Botta C, Scionti F, Talarico D, Altomare E, Gallo Cantafio ME, Zuccalà V, Maltese L, Todoerti K, Rossi M, Arbitrio M, Neri A, Tagliaferri P, Tassone P.

Leukemia. 2019 Feb;33(2):487-498. doi: 10.1038/s41375-018-0238-2. Epub 2018 Aug 17.

10.

A compendium of long non-coding RNAs transcriptional fingerprint in multiple myeloma.

Ronchetti D, Agnelli L, Pietrelli A, Todoerti K, Manzoni M, Taiana E, Neri A.

Sci Rep. 2018 Apr 26;8(1):6557. doi: 10.1038/s41598-018-24701-8.

11.

Pathogenicity of In Vivo Generated Intestinal Th17 Lymphocytes is IFNγ Dependent.

Nizzoli G, Burrello C, Cribiù FM, Lovati G, Ercoli G, Botti F, Trombetta E, Porretti L, Todoerti K, Neri A, Giuffrè MR, Geginat J, Vecchi M, Rescigno M, Paroni M, Caprioli F, Facciotti F.

J Crohns Colitis. 2018 Jul 30;12(8):981-992. doi: 10.1093/ecco-jcc/jjy051.

12.

Correction: miR-451a is underexpressed and targets AKT/mTOR pathway in papillary thyroid carcinoma.

Minna E, Romeo P, Dugo M, De Cecco L, Todoerti K, Pilotti S, Perrone F, Seregni E, Agnelli L, Neri A, Greco A, Borrello MG.

Oncotarget. 2018 Feb 23;9(15):12534. doi: 10.18632/oncotarget.24557. eCollection 2018 Feb 23.

13.

Depletion of SIRT6 enzymatic activity increases acute myeloid leukemia cells' vulnerability to DNA-damaging agents.

Cagnetta A, Soncini D, Orecchioni S, Talarico G, Minetto P, Guolo F, Retali V, Colombo N, Carminati E, Clavio M, Miglino M, Bergamaschi M, Nahimana A, Duchosal M, Todoerti K, Neri A, Passalacqua M, Bruzzone S, Nencioni A, Bertolini F, Gobbi M, Lemoli RM, Cea M.

Haematologica. 2018 Jan;103(1):80-90. doi: 10.3324/haematol.2017.176248. Epub 2017 Oct 12.

14.

Targeting COPZ1 non-oncogene addiction counteracts the viability of thyroid tumor cells.

Anania MC, Cetti E, Lecis D, Todoerti K, Gulino A, Mauro G, Di Marco T, Cleris L, Pagliardini S, Manenti G, Belmonte B, Tripodo C, Neri A, Greco A.

Cancer Lett. 2017 Dec 1;410:201-211. doi: 10.1016/j.canlet.2017.09.024. Epub 2017 Sep 23.

PMID:
28951131
15.

EphA3 targeting reduces in vitro adhesion and invasion and in vivo growth and angiogenesis of multiple myeloma cells.

La Rocca F, Airoldi I, Di Carlo E, Marotta P, Falco G, Simeon V, Laurenzana I, Trino S, De Luca L, Todoerti K, Villani O, Lackmann M, D'Auria F, Frassoni F, Neri A, Del Vecchio L, Musto P, Cilloni D, Caivano A.

Cell Oncol (Dordr). 2017 Oct;40(5):483-496. doi: 10.1007/s13402-017-0338-4. Epub 2017 Jul 18.

16.

IL21R expressing CD14+CD16+ monocytes expand in multiple myeloma patients leading to increased osteoclasts.

Bolzoni M, Ronchetti D, Storti P, Donofrio G, Marchica V, Costa F, Agnelli L, Toscani D, Vescovini R, Todoerti K, Bonomini S, Sammarelli G, Vecchi A, Guasco D, Accardi F, Palma BD, Gamberi B, Ferrari C, Neri A, Aversa F, Giuliani N.

Haematologica. 2017 Apr;102(4):773-784. doi: 10.3324/haematol.2016.153841. Epub 2017 Jan 5.

17.

In Silico Characterization of miRNA and Long Non-Coding RNA Interplay in Multiple Myeloma.

Ronchetti D, Manzoni M, Todoerti K, Neri A, Agnelli L.

Genes (Basel). 2016 Nov 29;7(12). pii: E107.

18.

Primary plasma cell leukemia 2.0: advances in biology and clinical management.

Neri A, Todoerti K, Lionetti M, Simeon V, Barbieri M, Nozza F, Vona G, Pompa A, Baldini L, Musto P.

Expert Rev Hematol. 2016 Nov;9(11):1063-1073. Epub 2016 Oct 24. Review.

PMID:
27759436
19.

Cutaneous localization in multiple myeloma in the context of bortezomib-based treatment: how do myeloma cells escape from the bone marrow to the skin?

Marchica V, Accardi F, Storti P, Mancini C, Martella E, Dalla Palma B, Bolzoni M, Todoerti K, Marcatti M, Schifano C, Bonomini S, Sammarelli G, Neri A, Ponzoni M, Aversa F, Giuliani N.

Int J Hematol. 2017 Jan;105(1):104-108. doi: 10.1007/s12185-016-2104-1. Epub 2016 Oct 3.

PMID:
27699576
20.

Time-course gene expression data on the transcriptional effects of Aminaphtone on ECV304 endothelial cells.

Salazar G, Bellocchi C, Todoerti K, Saporiti F, Piacentini L, Scorza R, Colombo GI.

Data Brief. 2016 Jul 2;8:836-50. doi: 10.1016/j.dib.2016.06.051. eCollection 2016 Sep.

21.

Multiple myeloma-derived Jagged ligands increases autocrine and paracrine interleukin-6 expression in bone marrow niche.

Colombo M, Galletti S, Bulfamante G, Falleni M, Tosi D, Todoerti K, Lazzari E, Crews LA, Jamieson CH, Ravaioli S, Baccianti F, Garavelli S, Platonova N, Neri A, Chiaramonte R.

Oncotarget. 2016 Aug 30;7(35):56013-56029. doi: 10.18632/oncotarget.10820.

22.

Galectin-1 suppression delineates a new strategy to inhibit myeloma-induced angiogenesis and tumoral growth in vivo.

Storti P, Marchica V, Airoldi I, Donofrio G, Fiorini E, Ferri V, Guasco D, Todoerti K, Silbermann R, Anderson JL, Zhao W, Agnelli L, Bolzoni M, Martella E, Mancini C, Campanini N, Noonan DM, Petronini PG, Neri A, Aversa F, Roodman GD, Giuliani N.

Leukemia. 2016 Dec;30(12):2351-2363. doi: 10.1038/leu.2016.137. Epub 2016 May 20.

PMID:
27311934
23.

Dependence on glutamine uptake and glutamine addiction characterize myeloma cells: a new attractive target.

Bolzoni M, Chiu M, Accardi F, Vescovini R, Airoldi I, Storti P, Todoerti K, Agnelli L, Missale G, Andreoli R, Bianchi MG, Allegri M, Barilli A, Nicolini F, Cavalli A, Costa F, Marchica V, Toscani D, Mancini C, Martella E, Dall'Asta V, Donofrio G, Aversa F, Bussolati O, Giuliani N.

Blood. 2016 Aug 4;128(5):667-79. doi: 10.1182/blood-2016-01-690743. Epub 2016 Jun 6.

24.

Gene expression profiling reveals novel protective effects of Aminaphtone on ECV304 endothelial cells.

Salazar G, Bellocchi C, Todoerti K, Saporiti F, Piacentini L, Scorza R, Colombo GI.

Eur J Pharmacol. 2016 Jul 5;782:59-69. doi: 10.1016/j.ejphar.2016.04.018. Epub 2016 Apr 12.

25.

Primary Plasma Cell Leukemia: Identity Card 2016.

Musto P, Simeon V, Todoerti K, Neri A.

Curr Treat Options Oncol. 2016 Apr;17(4):19. doi: 10.1007/s11864-016-0392-6. Review.

PMID:
26995215
26.

Distinct lncRNA transcriptional fingerprints characterize progressive stages of multiple myeloma.

Ronchetti D, Agnelli L, Taiana E, Galletti S, Manzoni M, Todoerti K, Musto P, Strozzi F, Neri A.

Oncotarget. 2016 Mar 22;7(12):14814-30. doi: 10.18632/oncotarget.7442.

27.

miR-451a is underexpressed and targets AKT/mTOR pathway in papillary thyroid carcinoma.

Minna E, Romeo P, Dugo M, De Cecco L, Todoerti K, Pilotti S, Perrone F, Seregni E, Agnelli L, Neri A, Greco A, Borrello MG.

Oncotarget. 2016 Mar 15;7(11):12731-47. doi: 10.18632/oncotarget.7262. Review. Erratum in: Oncotarget. 2018 Feb 23;9(15):12534.

28.

Molecular spectrum of TP53 mutations in plasma cell dyscrasias by next generation sequencing: an Italian cohort study and overview of the literature.

Lionetti M, Barbieri M, Manzoni M, Fabris S, Bandini C, Todoerti K, Nozza F, Rossi D, Musto P, Baldini L, Neri A.

Oncotarget. 2016 Apr 19;7(16):21353-61. doi: 10.18632/oncotarget.7241.

29.

A progression-risk score to predict treatment-free survival for early stage chronic lymphocytic leukemia patients.

Gentile M, Shanafelt TD, Cutrona G, Molica S, Tripepi G, Alvarez I, Mauro FR, Di Renzo N, Di Raimondo F, Vincelli I, Todoerti K, Matis S, Musolino C, Fabris S, Vigna E, Levato L, Zupo S, Angrilli F, Consoli U, Festini G, Longo G, Cortelezzi A, Arcari A, Federico M, Mannina D, Recchia AG, Neri A, Kay NE, Ferrarini M, Morabito F.

Leukemia. 2016 Jun;30(6):1440-3. doi: 10.1038/leu.2015.333. Epub 2015 Dec 9. No abstract available.

PMID:
26648537
30.

Disentangling the microRNA regulatory milieu in multiple myeloma: integrative genomics analysis outlines mixed miRNA-TF circuits and pathway-derived networks modulated in t(4;14) patients.

Calura E, Bisognin A, Manzoni M, Todoerti K, Taiana E, Sales G, Morgan GJ, Tonon G, Amodio N, Tassone P, Neri A, Agnelli L, Romualdi C, Bortoluzzi S.

Oncotarget. 2016 Jan 19;7(3):2367-78. doi: 10.18632/oncotarget.6151.

31.

Compendium of FAM46C gene mutations in plasma cell dyscrasias.

Barbieri M, Manzoni M, Fabris S, Ciceri G, Todoerti K, Simeon V, Musto P, Cortelezzi A, Baldini L, Neri A, Lionetti M.

Br J Haematol. 2016 Aug;174(4):642-5. doi: 10.1111/bjh.13793. Epub 2015 Oct 12. No abstract available.

PMID:
26456599
32.

Identification of thyroid tumor cell vulnerabilities through a siRNA-based functional screening.

Anania M, Gasparri F, Cetti E, Fraietta I, Todoerti K, Miranda C, Mazzoni M, Re C, Colombo R, Ukmar G, Camisasca S, Pagliardini S, Pierotti M, Neri A, Galvani A, Greco A.

Oncotarget. 2015 Oct 27;6(33):34629-48. doi: 10.18632/oncotarget.5282.

33.

A compendium of DIS3 mutations and associated transcriptional signatures in plasma cell dyscrasias.

Lionetti M, Barbieri M, Todoerti K, Agnelli L, Fabris S, Tonon G, Segalla S, Cifola I, Pinatel E, Tassone P, Musto P, Baldini L, Neri A.

Oncotarget. 2015 Sep 22;6(28):26129-41. doi: 10.18632/oncotarget.4674.

34.

Molecular Classification and Pharmacogenetics of Primary Plasma Cell Leukemia: An Initial Approach toward Precision Medicine.

Simeon V, Todoerti K, La Rocca F, Caivano A, Trino S, Lionetti M, Agnelli L, De Luca L, Laurenzana I, Neri A, Musto P.

Int J Mol Sci. 2015 Jul 30;16(8):17514-34. doi: 10.3390/ijms160817514. Review.

35.

Notch pathway promotes ovarian cancer growth and migration via CXCR4/SDF1α chemokine system.

Chiaramonte R, Colombo M, Bulfamante G, Falleni M, Tosi D, Garavelli S, De Simone D, Vigolo E, Todoerti K, Neri A, Platonova N.

Int J Biochem Cell Biol. 2015 Sep;66:134-40. doi: 10.1016/j.biocel.2015.07.015. Epub 2015 Jul 30.

PMID:
26235278
36.

Molecular spectrum of BRAF, NRAS and KRAS gene mutations in plasma cell dyscrasias: implication for MEK-ERK pathway activation.

Lionetti M, Barbieri M, Todoerti K, Agnelli L, Marzorati S, Fabris S, Ciceri G, Galletti S, Milesi G, Manzoni M, Mazzoni M, Greco A, Tonon G, Musto P, Baldini L, Neri A.

Oncotarget. 2015 Sep 15;6(27):24205-17.

37.

Whole-exome sequencing of primary plasma cell leukemia discloses heterogeneous mutational patterns.

Cifola I, Lionetti M, Pinatel E, Todoerti K, Mangano E, Pietrelli A, Fabris S, Mosca L, Simeon V, Petrucci MT, Morabito F, Offidani M, Di Raimondo F, Falcone A, Caravita T, Battaglia C, De Bellis G, Palumbo A, Musto P, Neri A.

Oncotarget. 2015 Jul 10;6(19):17543-58.

38.

The ribonuclease DIS3 promotes let-7 miRNA maturation by degrading the pluripotency factor LIN28B mRNA.

Segalla S, Pivetti S, Todoerti K, Chudzik MA, Giuliani EC, Lazzaro F, Volta V, Lazarevic D, Musco G, Muzi-Falconi M, Neri A, Biffo S, Tonon G.

Nucleic Acids Res. 2015 May 26;43(10):5182-93. doi: 10.1093/nar/gkv387. Epub 2015 Apr 29.

39.

Prospective validation of predictive value of abdominal computed tomography scan on time to first treatment in Rai 0 chronic lymphocytic leukemia patients: results of the multicenter O-CLL1-GISL study.

Gentile M, Cutrona G, Molica S, Ilariucci F, Mauro FR, Di Renzo N, Di Raimondo F, Vincelli I, Todoerti K, Matis S, Musolino C, Fabris S, Lionetti M, Levato L, Zupo S, Angrilli F, Consoli U, Festini G, Longo G, Cortelezzi A, Musto P, Federico M, Neri A, Ferrarini M, Morabito F.

Eur J Haematol. 2016 Jan;96(1):36-45. doi: 10.1111/ejh.12545. Epub 2015 Mar 31.

PMID:
25753656
40.

Notch signaling drives multiple myeloma induced osteoclastogenesis.

Colombo M, Thümmler K, Mirandola L, Garavelli S, Todoerti K, Apicella L, Lazzari E, Lancellotti M, Platonova N, Akbar M, Chiriva-Internati M, Soutar R, Neri A, Goodyear CS, Chiaramonte R.

Oncotarget. 2014 Nov 15;5(21):10393-406.

41.

Is ZAP70 still a key prognostic factor in early stage chronic lymphocytic leukaemia? Results of the analysis from a prospective multicentre observational study.

Morabito F, Cutrona G, Gentile M, Fabris S, Matis S, Vigna E, Todoerti K, Colombo M, Recchia AG, Bossio S, De Stefano L, Ilariucci F, Cortelezzi A, Consoli U, Vincelli I, Pesce EA, Musolino C, Molica S, Di Raimondo F, Neri A, Ferrarini M.

Br J Haematol. 2015 Feb;168(3):455-9. doi: 10.1111/bjh.13117. Epub 2014 Sep 11. No abstract available.

PMID:
25208809
42.

Molecular events underlying interleukin-6 independence in a subclone of the CMA-03 multiple myeloma cell line.

Verdelli D, Nobili L, Todoerti K, Mosca L, Fabris S, D'Anca M, Pellegrino E, Piva R, Inghirami G, Capelli C, Introna M, Baldini L, Chiaramonte R, Lombardi L, Neri A.

Genes Chromosomes Cancer. 2014 Feb;53(2):154-67. doi: 10.1002/gcc.22127. Epub 2013 Nov 5.

PMID:
24327544
43.

Lenalidomide and low-dose dexamethasone for newly diagnosed primary plasma cell leukemia.

Musto P, Simeon V, Martorelli MC, Petrucci MT, Cascavilla N, Di Raimondo F, Caravita T, Morabito F, Offidani M, Olivieri A, Benevolo G, Mina R, Guariglia R, D'Arena G, Mansueto G, Filardi N, Nobile F, Levi A, Falcone A, Cavalli M, Pietrantuono G, Villani O, Bringhen S, Omedè P, Lerose R, Agnelli L, Todoerti K, Neri A, Boccadoro M, Palumbo A.

Leukemia. 2014 Jan;28(1):222-5. doi: 10.1038/leu.2013.241. Epub 2013 Aug 20. No abstract available.

PMID:
23958922
44.

Improved risk stratification in myeloma using a microRNA-based classifier.

Wu P, Agnelli L, Walker BA, Todoerti K, Lionetti M, Johnson DC, Kaiser M, Mirabella F, Wardell C, Gregory WM, Davies FE, Brewer D, Neri A, Morgan GJ.

Br J Haematol. 2013 Aug;162(3):348-59. doi: 10.1111/bjh.12394. Epub 2013 May 30.

PMID:
23718138
45.

Single-agent Smac-mimetic compounds induce apoptosis in B chronic lymphocytic leukaemia (B-CLL).

Scavullo C, Servida F, Lecis D, Onida F, Drago C, Ferrante L, Seneci P, Barcellini W, Lionetti M, Todoerti K, Neri A, Delia D, Deliliers GL.

Leuk Res. 2013 Jul;37(7):809-15. doi: 10.1016/j.leukres.2013.03.016. Epub 2013 Apr 22.

PMID:
23618690
46.

Biological and clinical relevance of miRNA expression signatures in primary plasma cell leukemia.

Lionetti M, Musto P, Di Martino MT, Fabris S, Agnelli L, Todoerti K, Tuana G, Mosca L, Gallo Cantafio ME, Grieco V, Bianchino G, D'Auria F, Statuto T, Mazzoccoli C, De Luca L, Petrucci MT, Offidani M, Di Raimondo F, Falcone A, Caravita T, Omede' P, Morabito F, Tassone P, Boccadoro M, Palumbo A, Neri A.

Clin Cancer Res. 2013 Jun 15;19(12):3130-42. doi: 10.1158/1078-0432.CCR-12-2043. Epub 2013 Apr 23.

47.

Transcriptional characterization of a prospective series of primary plasma cell leukemia revealed signatures associated with tumor progression and poorer outcome.

Todoerti K, Agnelli L, Fabris S, Lionetti M, Tuana G, Mosca L, Lombardi L, Grieco V, Bianchino G, D'Auria F, Statuto T, Mazzoccoli C, De Luca L, Petrucci MT, Morabito F, Offidani M, Di Raimondo F, Falcone A, Omede' P, Tassone P, Boccadoro M, Palumbo A, Neri A, Musto P.

Clin Cancer Res. 2013 Jun 15;19(12):3247-58. doi: 10.1158/1078-0432.CCR-12-3461. Epub 2013 Apr 18.

48.

The expression pattern of small nucleolar and small Cajal body-specific RNAs characterizes distinct molecular subtypes of multiple myeloma.

Ronchetti D, Todoerti K, Tuana G, Agnelli L, Mosca L, Lionetti M, Fabris S, Colapietro P, Miozzo M, Ferrarini M, Tassone P, Neri A.

Blood Cancer J. 2012 Nov 23;2:e96. doi: 10.1038/bcj.2012.41.

49.

Immunomodulatory drugs lenalidomide and pomalidomide inhibit multiple myeloma-induced osteoclast formation and the RANKL/OPG ratio in the myeloma microenvironment targeting the expression of adhesion molecules.

Bolzoni M, Storti P, Bonomini S, Todoerti K, Guasco D, Toscani D, Agnelli L, Neri A, Rizzoli V, Giuliani N.

Exp Hematol. 2013 Apr;41(4):387-97.e1. doi: 10.1016/j.exphem.2012.11.005. Epub 2012 Nov 23.

PMID:
23178378
50.

Genome-wide analysis of primary plasma cell leukemia identifies recurrent imbalances associated with changes in transcriptional profiles.

Mosca L, Musto P, Todoerti K, Barbieri M, Agnelli L, Fabris S, Tuana G, Lionetti M, Bonaparte E, Sirchia SM, Grieco V, Bianchino G, D'Auria F, Statuto T, Mazzoccoli C, De Luca L, Petrucci MT, Morabito F, Offidani M, Di Raimondo F, Falcone A, Caravita T, Omedè P, Boccadoro M, Palumbo A, Neri A.

Am J Hematol. 2013 Jan;88(1):16-23. doi: 10.1002/ajh.23339. Epub 2012 Oct 9.

Supplemental Content

Loading ...
Support Center